DE
Therapeutic Areas
ADC Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZYNLONTA® (loncastuximab tesirine-lpyl) | Relapsed or Refractory Large B-cell Lymphoma (after ≥2 prior therapies) | Approved |
| PSMA-targeting ADC (ADCT-901) | Prostate Cancer and other PSMA-expressing Solid Tumors | Pre-IND |